

**APPLICATION FOR NEW COURSE**

1. Submitted by the College of Public Health Date: 3/3/08

Department/Division proposing course: Epidemiology

2. Proposed designation and Bulletin description of this course:

a. Prefix and Number CPH 613

b. Title\* Molecular Epidemiology, Cancer Prevention & Control

\*If title is longer than 24 characters, write a sensible title (24 characters or less) for use on transcripts:

Molecular Epi

c. Courses must be described by at least one of the categories below. Include the number of actual contact hours per week for each category, as applicable.

- ( ) CLINICAL    ( ) COLLOQUIUM    ( ) DISCUSSION    ( ) LABORATORY    (X) LECTURE  
 ( ) INDEPEND. STUDY    ( ) PRACTICUM    ( ) RECITATION    ( ) RESEARCH    ( ) RESIDENCY  
 ( ) SEMINAR    ( ) STUDIO    ( ) OTHER – Please explain: \_\_\_\_\_

d. Please choose a grading system:  Letter (A, B, C, etc.)     Pass/Fail

e. Number of credit hours: 3

f. Is this course repeatable? YES  NO  If YES, maximum number of credit hours: \_\_\_\_\_

g. Course description:

This course consists of didactic lectures, journal clubs, and small group round table discussions related to the principles of underlying biomarker discovery and development for cancer prevention and control. The overarching goal of this course will be to assess how biomarkers are developed and used for the risk assessment, early detection, diagnosis, prognosis, and theragnosis of cancer.

h. Prerequisite(s), if any:

Introduction to Epidemiology (CPH 605) or consent of instructor

i. Will this course be offered through Distance Learning? YES  NO

If YES, please circle one of the methods below that reflects how the majority of the course content will be delivered:

- Internet/Web-based    Interactive video    Extended campus    Kentucky Educational Television (KET/teleweb)    Other

Please describe "Other": \_\_\_\_\_

3. Teaching method:  N/A or  Community-Based Experience     Service Learning Component     Both

4. To be cross-listed as: \_\_\_\_\_  
Prefix and Number

\_\_\_\_\_  
Signature of chair of cross-listing department

APPLICATION FOR NEW COURSE

RECEIVED

DEC 10 08

OFFICE OF THE SENATE COUNCIL

5. Requested effective date (term/year): Fall / 2008
6. Course to be offered (please check all that apply):  Fall  Spring  Summer
7. Will the course be offered every year?  YES  NO  
 If NO, please explain: \_\_\_\_\_
8. Why is this course needed?  
This course will be a selective in the Epidemiology track.
- 
9. a. By whom will the course be taught? Andre Baron
- b. Are facilities for teaching the course now available?  YES  NO  
 If NO, what plans have been made for providing them?  
 \_\_\_\_\_
10. What yearly enrollment may be reasonably anticipated?  
15-20
11. a. Will this course serve students primarily within the department?  Yes  No
- b. Will it be of interest to a significant number of students outside the department?  YES  NO  
 If YES, please explain.  
Students in other Public Health tracks may be interested.
- 
12. Will the course serve as a University Studies Program course<sup>†</sup>?  YES  NO  
 If YES, under what Area? \_\_\_\_\_  
<sup>†</sup>AS OF SPRING 2007, THERE IS A MORATORIUM ON APPROVAL OF NEW COURSES FOR USP.
13. Check the category most applicable to this course:  
 traditional – offered in corresponding departments at universities elsewhere  
 relatively new – now being widely established  
 not yet to be found in many (or any) other universities
14. Is this course applicable to the requirements for at least one degree or certificate at UK?  Yes  No
15. Is this course part of a proposed new program?  YES  NO  
 If YES, please name: \_\_\_\_\_
16. Will adding this course change the degree requirements for ANY program on campus?  YES  NO  
 If YES<sup>‡</sup>, list below the programs that will require this course:

## APPLICATION FOR NEW COURSE

<sup>1</sup>In order to change the program(s), a program change form(s) must also be submitted.

17.  The major teaching objectives of the proposed course, syllabus and/or reference list to be used are attached.
18.  Check box if course is 400G or 500. If the course is 400G- or 500-level, you must include a syllabus showing differentiation for undergraduate and graduate students by (i) requiring additional assignments by the graduate students; and/or (ii) the establishment of different grading criteria in the course for graduate students. (See SR 3.1.4)

19. Within the department, who should be contacted for further information about the proposed new course?

Name: Andre Baron Phone: 323-1729 Email: a.baron@uky.edu

20. Signatures to report approvals:

4/30/2008  
DATE of Approval by Department Faculty

Thomas C. Tucker      Thomas C. Tucker  
printed name      Reported by Department Chair      signature

7-17-08  
DATE of Approval by College Faculty

Linda A. Alexander      Linda A. Alexander  
printed name      Reported by College Dean      signature

\* DATE of Approval by Undergraduate Council

printed name      Reported by Undergraduate Council Chair      signature

12/17/08  
\* DATE of Approval by Graduate Council

Brian Jackson      Brian Jackson  
printed name      Reported by Graduate Council Chair      signature

9/16/08  
\* DATE of Approval by Health Care Colleges Council (HCCC)

Heidi Anderson      Heidi Anderson  
printed name      Reported by Health Care Colleges Council Chair      signature

\* DATE of Approval by Senate Council

Reported by Office of the Senate Council

\* DATE of Approval by University Senate

Reported by Office of the Senate Council

\*If applicable, as provided by the *University Senate Rules*. (<http://www.uky.edu/USC/New/RulesandRegulationsMain.htm>)


Course Director Andre Baron, M.S., Ph.D., M.P.H.  
800 Rose Street  
Markey Cancer Center  
Ben F. Roach Building, Room 408  
Lexington, KY 40536-0093  
Office hours: M-F 8-12 noon by appointment

The course director and faculty will be available for consultation. Students are encouraged to consult with all participating faculty.

<u>Course Faculty</u>	<u>Phone</u>	<u>Email</u>
Andre Baron	323-1729	a.baron@uky.edu
Esther Black	323-5898	penni.black@uky.edu
Diane Davey	257-9547	ddavey2@email.uky.edu
Claudia Hopenhayn	296-6630	cmhope0@pop.uky.edu
Natasha Kyprianou	323-9812	nkypr2@uky.edu
Guo-Min Li	257-7053	gmli@uky.edu
Bert Lynn	257-2300 X287	bclynn2@uky.edu
David Mannino	323-3608	dmannino@uky.edu
Hollie Skaggs	323-1383	hsskag2@uky.edu

### Course Description & Structure

Molecular Epidemiology, Cancer Prevention and Control, is a 3-credit hour course consisting of didactic lectures, journal clubs, and small group round table discussions related to the principles underlying biomarker discovery and development for cancer prevention and control. The overarching goal of this course will be to assess how biomarkers are developed and used for the risk assessment, early detection, diagnosis, prognosis, and theragnosis of cancer. This course will meet once per week (2 1/2 hr session) with an overview and/or historical review of the weekly topic presented in a didactic lecture format during the first hour by the instructor. This will be followed by an oral student presentation of a current or historically relevant research publication during the second hour using the journal club format. Finally, a round table small group discussion format will be used to focus on questions and issues relevant to the topic during the final 1/2 hour. This active teaching/learning strategy effectively involves students in the learning and discovery process, in processing new information, and in holding students accountable for learned information by asking them immediately to apply their knowledge to discuss the topic. Problem centered learning puts learning into context and facilitates learning transfer by allowing students to organize and categorize information into meaningful units, to discover



relationships, and to extract and assimilate important points in an interactive and participatory venue.

### **Audience**

This course serves is designed primarily for graduate public health students with professional interests in molecular epidemiology as this topic relates to cancer prevention and control. This course also is appropriate for students in other related health professions (i.e., medicine, nursing, pharmacy) and the biological sciences.

### **Balance of Historic and Current Scientific Perspectives**

Given the rapid pace of progress in the biological and epidemiological sciences and the exponential growth rate of relevant literature, the general philosophy that is promoted within this course is to *teach less better*. The objective here is to lay a strong foundation in cancer molecular epidemiology with the clear understanding that what is particularly relevant and important today, may not be so tomorrow. Therefore, *emphasis is placed on developing paradigms and themes in molecular epidemiology*, as well as critical review and evaluation of issues at the forefront of modern molecular epidemiology and biology as they relate to cancer prevention and control.

### **Commitment, Accountability, and Responsibility**

Integral to this teaching philosophy is *Peer-Performance Assessment* and the *Teaching Learning Model*. These strategies create a climate in which all students are encouraged to develop their learning and teaching skills. This results in a classroom environment where students from diverse backgrounds feel welcome to fully participate in discussions and problem solving. In this way, desired student performances are tied directly to the efforts of the students themselves, to the involvement of students in the teaching-learning process, to the opportunities to make choices, and to the degree to which students interact with their peers and instructors. Emphasis is placed on organization and presentation skills, accountability tracking, peer assessment, and instructional feedback.

### **Course Requirements & Grading Criteria**

10% class participation, quizzes, & round table discussion  
30% journal club presentations  
30% journal topic essays  
30% term paper or student debate

1. Tests - There are no tests in this course.
2. Quizzes - Please be prepared to take a 5-minute quiz on the reading assignment at the beginning of each class.

## **Grading Scale for Graduate Students**

100-90% = A  
89.9-80% = B  
79.9-70% = C  
< 69.9% = E

3. Journal Club Presentations & Topic Essays - A schedule of student journal club presentations will be developed during the first class period. Journal club presentations will only be rescheduled for legitimate reasons accompanied by verifiable documentation. In addition to the oral presentation, students will be required to provide a copy of their presentation slides (or overheads) with speaker's notes to each person in the class as a handout packet at the time of the journal club. Students will be expected to attend all class sessions and to participate in discussions and/or problem sets related to the journal club. A topic essay (single-spaced 1-2 page limit; 10-12 pt font) will be due by 12:00 midnight on Friday for grading by the instructor. The topic essay should be e-mailed to Dr. Baron at a.baron@uky.edu.
4. Term Papers or Debate – Students in the course will elect to write a term paper or have a debate on a topic relevant to cancer molecular epidemiology at the beginning of the semester. The term paper due date or debate date will be announced during the first class period and shown on the course syllabus.
5. Grading - Journal club presentation grades will be based on peer and instructor assessment. Special topic essays and term papers that are not completed in a timely manner according to the class schedule will be subject to point deductions; 5 points will be deducted for each late day past the due date. The grading standards employed will be as follows. Students who perform in these ranges will receive the indicated grades.

A:	90-100%
B:	80-89%
C:	70-79%
D:	60-69%
E:	below 60%

Special topic essays can be submitted to the course director within one week (7 days) for a re-evaluation if it is deemed that a mistake has been made in the original grading. Submissions must be accompanied by a written explanation of the perceived mistake. Upon submission, the entire problem set or topic essay may be subject to re-evaluation and all questions therein may be re-graded.

### Course Text and Reference Materials

The instructors will provide all reading assignments.

**Reference books** (Placed on reserve in the Course Director's Office):

- Molecular Epidemiology: Principles and Practices, 1993, edited by Paul A. Schulte and Frederica P. Perera, Academic Press, San Diego
- Molecular Biology of the Cell, 4<sup>th</sup> Edition, 2002, edited by Bruce Alberts, Alexander Johnson, Julian Lewis, Martin Raff, Keith Roberts, and Peter Walter, Garland Science, New York

- The Biological Basis of Cancer, 2000, edited by Robert G. McKinnell, Ralph E. Parchment, Alan O. Perantoni, and G. Barry Pierce, Cambridge University Press, Cambridge
- The Biology of Cancer, 2007, edited by Robert A. Weinberg, Garland Science, Taylor & Francis Group, LLC

### College of Public Health Terminal Objectives in Epidemiology

Please refer to the College of Public Health student handbooks for information about general education program objectives (<http://www.ukcph.org/>). Students who take this course will be able to:

1. Assess the purpose and application of molecular epidemiology as it relates to cancer prevention and control.
2. Search and critically read and interpret publications in molecular epidemiology.
3. Identify and use appropriate epidemiological study designs and principles to address research questions in molecular epidemiology.
4. Assess how to collect and manage data for investigational molecular epidemiology studies.
5. Assess the statistical methods used to analyze molecular epidemiological data.
6. Interpret and clearly communicate molecular epidemiological research findings.
7. Assess any ethical issues that may confront molecular epidemiological studies.
8. Assess how the principles of molecular epidemiology are integrated into the practice of public health and medicine.

### Academic Integrity & Honesty

Academic honesty is fundamental to the activities and principles of a university. All members of the academic community must be confident that each person's work has been responsibly and honorably prepared, developed, and presented. Any effort to gain an advantage not given to all students is dishonest whether or not the effort is successful. The academic community regards academic dishonesty as an extremely serious matter, with serious consequences that range from a grade "E" to expulsion from the University. Both **cheating** and **plagiarism** are considered academic dishonesty. Cheating refers to any unauthorized assistance during examination questions to/from other student(s). Plagiarism is academic "theft", and includes not properly crediting another author for his/her work or idea. Any paraphrase or direct quotation from a published or unpublished work should be properly cited with a footnote or reference. Students must be particularly careful not to engage in plagiarism, even inadvertently, since computers and Internet web-browsing seem to facilitate this process.

The Department of Health Services Management, the College of Public Health, and the University of Kentucky place a premium on academic honesty. Please refer to the



University of Kentucky Student Rights and Responsibilities document  
([www.uky.edu/StudentAffairs/Code/part2.html](http://www.uky.edu/StudentAffairs/Code/part2.html)).

### **Student's with Disabilities**

If you have a documented disability that requires academic accommodations, please see me as soon as possible during scheduled office hours. In order to receive accommodations in this course, you must provide me with a Letter of Accommodation from the Disability Resource Center ([www.uky.edu/TLC/grants/uk\\_ed/services/drc.html](http://www.uky.edu/TLC/grants/uk_ed/services/drc.html)). If you have not already done so, please register with the Disability Resource Center (Room 2 Alumni Gym, 257-2754, [jkarnes@uky.edu](mailto:jkarnes@uky.edu)) for coordination of campus disability services available to students with disabilities.

### **Provisionality**

As Course Director, I reserve the right to clarify or amend these policies, in which case I will document the clarification or amendment in an email memorandum.



	<ul style="list-style-type: none"> <li>No association between genetic polymorphisms in insulin and insulin receptor substrate-1 and prostate cancer (Li, Cicek et al. 2005)</li> </ul>	
Week 6	<p>Cancer Susceptibility: DNA Damage and DNA Mismatch Repair Genes</p> <p><u>Readings</u></p> <ul style="list-style-type: none"> <li>Genetic alterations and DNA repair in human carcinogenesis (Dixon and Kopras 2004)</li> <li>Interrogating DNA repair in cancer risk assessment (Paz-Elizur, Brenner et al. 2005)</li> </ul> <p><u>Molecular Epidemiology Journal Club</u></p> <ul style="list-style-type: none"> <li>Polymorphisms in estrogen bioactivation, detoxification and oxidative DNA base excision repair genes and prostate cancer risk (Nock, Cicek et al. 2006)</li> <li>DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy (Olaussen, Dunant et al. 2006)</li> </ul>	Li
Week 7	<p>Cancer Risk Assessment, Screening &amp; Diagnosis with Serum Biomarkers</p> <p><u>Readings</u></p> <ul style="list-style-type: none"> <li>Principles of bladder cancer screening in an intervention trial (Hulka 1990)</li> <li>Statistical considerations in cancer screening programs (Prorok, Connor et al. 1990)</li> <li>Phases of Biomarker Development for Early Detection of Cancer (Pepe, Etzioni et al. 2001)</li> </ul> <p><u>Molecular Epidemiology Journal Club</u></p> <ul style="list-style-type: none"> <li>Alteration of the serum levels of the epidermal growth factor receptor and its ligands in patients with non-small cell lung cancer and head and neck carcinoma (Lemos-Gonzalez, Rodriguez-Berrocal et al. 2007)</li> <li>Shared immunoproteome for ovarian cancer diagnostics and immunotherapy: potential theranostic approach to cancer (Philip, Murthy et al. 2007)</li> </ul>	Baron
Week 8	<p>Risk Assessment: Biomarkers of Exposure – Arsenic and Bladder Cancer</p> <p><u>Readings</u></p> <ul style="list-style-type: none"> <li>Micronuclei in exfoliated bladder cells among individuals chronically exposed to arsenic in drinking water (Moore, Smith et al. 1997)</li> <li>Arsenic methylation and bladder cancer risk in case-control studies in Argentina and the United States (Steinmaus, Bates et al. 2006)</li> </ul> <p><u>Molecular Epidemiology Journal Club</u></p> <ul style="list-style-type: none"> <li>Interaction between environmental tobacco smoke and arsenic methylation ability on the risk of bladder cancer (Chen, Su et al. 2005)</li> </ul>	Hopenhayn
Week 9	<p>Cancer Screening: HPV DNA Testing, Cytology, and Cervical Cancer</p> <p><u>Readings</u></p> <ul style="list-style-type: none"> <li>Management of women who test positive for high-risk types of human papillomavirus: the HART study (Cuzick,</li> </ul>	Davey

	<p>Szarewski et al. 2003)</p> <ul style="list-style-type: none"> <li>• Overview of the European and North American studies on HPV testing in primary cervical cancer screening (Cuzick, Clavel et al. 2006)</li> </ul> <p><u>Molecular Epidemiology Journal Club</u></p> <ul style="list-style-type: none"> <li>• Human papillomavirus prevalence and type distribution in male anogenital sites and semen (Nielson, Flores et al. 2007)</li> </ul>	
Week 10	<p>Risk Assessment: Biomarkers of Chronic Obstructive Pulmonary Disease and Lung Cancer</p> <p><u>Readings</u></p> <ul style="list-style-type: none"> <li>• Carcinogenicity of metal compounds: possible role of DNA repair inhibition (Hartwig 1998)</li> <li>• Urinary cadmium levels predict lower lung function in current and former smokers: data from the Third National Health and Nutrition Examination Survey (Mannino, Holguin et al. 2004)</li> </ul> <p><u>Molecular Epidemiology Journal Club</u></p> <ul style="list-style-type: none"> <li>• Profiling serum biomarkers in patients with COPD: associations with clinical parameters (Pinto-Plata, Toso et al. 2007)</li> </ul>	Mannino
Week 11	<p>Cancer Diagnosis &amp; Prognosis: Tumor Suppressors, Oncogenes, and Cell Cycle Regulatory Proteins</p> <p><u>Readings</u></p> <ul style="list-style-type: none"> <li>• Tumor Suppressor Genes (Ruddon 1995)</li> <li>• Oncogenes (Ruddon 1995)</li> <li>• The cell cycle: accelerators, brakes, and checkpoints (Ivanchuk and Rutka 2004)</li> <li>• Regulation of telomerase by telomeric proteins (Smogorzewska and de Lange 2004)</li> </ul> <p><u>Molecular Epidemiology Journal Club</u></p> <ul style="list-style-type: none"> <li>• Younger age of cancer initiation is associated with shorter telomere length in Li-Fraumeni syndrome (Tabori, Nanda et al. 2007)</li> <li>• Analysis of p53 protein expression levels on ovarian cancer tissue microarray using automated quantitative analysis elucidates prognostic patient subsets (Psyrris, Kountourakis et al. 2007)</li> </ul>	Baron
Week 12	<p>Cancer Diagnosis &amp; Prognosis: Apoptotic Regulatory Proteins</p> <p><u>Readings</u></p> <ul style="list-style-type: none"> <li>• Mitochondria: releasing power for life and unleashing the machineries of death (Newmeyer and Ferguson-Miller 2003)</li> <li>• Medicine. Targeting apoptotic pathways in cancer cells (Denicourt and Dowdy 2004)</li> <li>• Apoptosis as a novel target for cancer chemoprevention (Sun, Hail et al. 2004)</li> </ul> <p><u>Molecular Epidemiology Journal Club</u></p> <ul style="list-style-type: none"> <li>• Influence of survivin and caspase-3 on cell apoptosis and prognosis in gastric carcinoma. (Li, Wang et al. 2004)</li> </ul>	Kyprianou
Week 13	<p>Cancer Diagnosis &amp; Prognosis: MicroRNAs, DNA Methylation &amp; Epigenetic Therapy</p>	Skaggs

	<p><u>Readings</u></p> <ul style="list-style-type: none"> <li>• The power and the promise of DNA methylation markers (Laird 2003)</li> <li>• Epigenetics and human disease: translating basic biology into clinical applications (Rodenhiser and Mann 2006)</li> <li>• DNA methylation as a therapeutic target in cancer (Issa 2007)</li> <li>• miRNA profiling for diagnosis and prognosis of human cancer (Jay, Nemunaitis et al. 2007)</li> </ul> <p><u>Molecular Epidemiology Journal Club</u></p> <ul style="list-style-type: none"> <li>• Association of genetic variants of O6-methylguanine-DNA methyltransferase with risk of lung cancer in non-Hispanic Whites. (Wang, Liu et al. 2006)</li> <li>• Epigenetic inactivation of BRCA1 is associated with aberrant expression of CTCF and DNA methyltransferase (DNMT3B) in some sporadic breast tumours (Butcher and Rodenhiser 2007)</li> </ul>	
Week 14	<p>Cancer Theragnosis: Tumor &amp; Serum Biomarkers</p> <p><u>Readings</u></p> <ul style="list-style-type: none"> <li>• Metabolomics-based systems biology and personalized medicine: moving towards n = 1 clinical trials? (van der Greef, Hankemeier et al. 2006)</li> <li>• Mapping translational research in personalized therapeutics: from molecular markers to health policy (Ozdemir, Williams-Jones et al. 2007)</li> </ul> <p><u>Molecular Epidemiology Journal Club</u></p> <ul style="list-style-type: none"> <li>• Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study. (Taguchi, Solomon et al. 2007)</li> <li>• Serum proteomic classifier for predicting response to epidermal growth factor receptor inhibitor therapy: have we built a better mousetrap? (Tsao, Liu et al. 2007)</li> <li>• A 25-signal proteomic signature and outcome for patients with resected non-small-cell lung cancer. (Yanagisawa, Tomida et al. 2007)</li> </ul>	Baron
Week 15	<p>Transitional Studies: Biospecimens &amp; Bioinformatics</p> <p><u>Readings</u></p> <ul style="list-style-type: none"> <li>• Biorepository and biospecimen science: a new focus for CEBP (Vaught 2006)</li> <li>• Sample collection, processing, and storage for large-scale studies: biorepositories to support cancer research (Ambrosone 2006)</li> </ul> <p><u>Molecular Epidemiology Journal Club</u></p> <ul style="list-style-type: none"> <li>• Serum levels of insulin-like growth factor-I and insulin-like growth factor-I binding protein-3: quality control for studies of stored serum. (Berrigan, Potischman et al. 2007)</li> </ul> <p><u>Molecular Epidemiology Debate</u></p>	Baron
Week 16	Term Paper Deadline	Student Teams 12:00 Midnight

## References

- Ambrosone, C. B. (2006). "Sample collection, processing, and storage for large-scale studies: biorepositories to support cancer research." *Cancer Epidemiol Biomarkers Prev* 15(9): 1574.
- Ansari, M. and M. Krajinovic (2007). "Pharmacogenomics in cancer treatment defining genetic bases for inter-individual differences in responses to chemotherapy." *Curr Opin Pediatr* 19(1): 15-22.
- Aschengrau, A. and G. R. Seage III (2003). Critical Review of Epidemiologic Studies. *Essentials of Epidemiology in Public Health*. Sudbury, MA, Jones and Bartlett Publishers: 348-374.
- Berrigan, D., N. Potischman, et al. (2007). "Serum levels of insulin-like growth factor-I and insulin-like growth factor-I binding protein-3: quality control for studies of stored serum." *Cancer Epidemiol Biomarkers Prev* 16(5): 1017-22.
- Bielas, J. H., K. R. Loeb, et al. (2006). "Human cancers express a mutator phenotype." *Proc Natl Acad Sci U S A* 103(48): 18238-42.
- Butcher, D. T. and D. I. Rodenhiser (2007). "Epigenetic inactivation of BRCA1 is associated with aberrant expression of CTCF and DNA methyltransferase (DNMT3B) in some sporadic breast tumours." *Eur J Cancer* 43(1): 210-9.
- Caillier, B., J. Lepine, et al. (2007). "A pharmacogenomics study of the human estrogen glucuronosyltransferase UGT1A3." *Pharmacogenet Genomics* 17(7): 481-495.
- Chen, Y. C., H. J. Su, et al. (2005). "Interaction between environmental tobacco smoke and arsenic methylation ability on the risk of bladder cancer." *Cancer Causes Control* 16(2): 75-81.
- Cuzick, J., C. Clavel, et al. (2006). "Overview of the European and North American studies on HPV testing in primary cervical cancer screening." *Int J Cancer* 119(5): 1095-101.
- Cuzick, J., A. Szarewski, et al. (2003). "Management of women who test positive for high-risk types of human papillomavirus: the HART study." *Lancet* 362(9399): 1871-6.
- Denicourt, C. and S. F. Dowdy (2004). "Medicine. Targeting apoptotic pathways in cancer cells." *Science* 305(5689): 1411-3.
- Dixon, K. and E. Koprass (2004). "Genetic alterations and DNA repair in human carcinogenesis." *Semin Cancer Biol* 14(6): 441-8.
- Engels, E. A., X. Wu, et al. (2007). "Systematic evaluation of genetic variants in the inflammation pathway and risk of lung cancer." *Cancer Res* 67(13): 6520-7.
- Erichsen, H. C. and S. J. Chanock (2004). "SNPs in cancer research and treatment." *Br J Cancer* 90(4): 747-51.
- Hartwig, A. (1998). "Carcinogenicity of metal compounds: possible role of DNA repair inhibition." *Toxicol Lett* 102-103: 235-9.
- Hulka, B. S. (1990). "Principles of bladder cancer screening in an intervention trial." *J Occup Med* 32(9): 812-6.
- Hurst, R. E. and J. Y. Rao (1993). *Molecular Biology in Epidemiology. Molecular Epidemiology: Principles and Practices*, Academic Press, Inc.: 45-79.
- Hursting, S. D., T. J. Slaga, et al. (1999). "Mechanism-based cancer prevention approaches: targets, examples, and the use of transgenic mice." *J Natl Cancer Inst* 91(3): 215-25.
- Issa, J. P. (2007). "DNA methylation as a therapeutic target in cancer." *Clin Cancer Res* 13(6): 1634-7.
- Ivanchuk, S. M. and J. T. Rutka (2004). "The cell cycle: accelerators, brakes, and checkpoints." *Neurosurgery* 54(3): 692-9; discussion 699-700.
- Jay, C., J. Nemunaitis, et al. (2007). "miRNA profiling for diagnosis and prognosis of human cancer." *DNA Cell Biol* 26(5): 293-300.
- Laird, P. W. (2003). "The power and the promise of DNA methylation markers." *Nat Rev Cancer* 3(4): 253-66.
- Lemos-Gonzalez, Y., F. J. Rodriguez-Berrocal, et al. (2007). "Alteration of the serum levels of the epidermal growth factor receptor and its ligands in patients with non-small cell lung cancer and head and neck carcinoma." *Br J Cancer* 96(10): 1569-78.
- Li, L., M. S. Cicek, et al. (2005). "No association between genetic polymorphisms in insulin and insulin receptor substrate-1 and prostate cancer." *Cancer Epidemiol Biomarkers Prev* 14(10): 2462-3.

- Li, Y. H., C. Wang, et al. (2004). "Influence of survivin and caspase-3 on cell apoptosis and prognosis in gastric carcinoma." World J Gastroenterol 10(13): 1984-8.
- Lou, J., N. Fatima, et al. (2006). "Proteomic profiling identifies cyclooxygenase-2-independent global proteomic changes by celecoxib in colorectal cancer cells." Cancer Epidemiol Biomarkers Prev 15(9): 1598-606.
- Mannino, D. M., F. Holguin, et al. (2004). "Urinary cadmium levels predict lower lung function in current and former smokers: data from the Third National Health and Nutrition Examination Survey." Thorax 59(3): 194-8.
- Moore, L. E., A. H. Smith, et al. (1997). "Micronuclei in exfoliated bladder cells among individuals chronically exposed to arsenic in drinking water." Cancer Epidemiol Biomarkers Prev 6(1): 31-6.
- Newmeyer, D. D. and S. Ferguson-Miller (2003). "Mitochondria: releasing power for life and unleashing the machineries of death." Cell 112(4): 481-90.
- Nielson, C. M., R. Flores, et al. (2007). "Human papillomavirus prevalence and type distribution in male anogenital sites and semen." Cancer Epidemiol Biomarkers Prev 16(6): 1107-14.
- Nock, N. L., M. S. Cicek, et al. (2006). "Polymorphisms in estrogen bioactivation, detoxification and oxidative DNA base excision repair genes and prostate cancer risk." Carcinogenesis 27(9): 1842-8.
- Olaussen, K. A., A. Dunant, et al. (2006). "DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy." N Engl J Med 355(10): 983-91.
- Ozdemir, V., B. Williams-Jones, et al. (2007). "Mapping translational research in personalized therapeutics: from molecular markers to health policy." Pharmacogenomics 8(2): 177-185.
- Paz-Elizur, T., D. E. Brenner, et al. (2005). "Interrogating DNA repair in cancer risk assessment." Cancer Epidemiol Biomarkers Prev 14(7): 1585-7.
- Pepe, M. S., R. Etzioni, et al. (2001). "Phases of Biomarker Development for Early Detection of Cancer." JNCI Cancer Spectrum 93(14): 1054-1061.
- Philip, R., S. Murthy, et al. (2007). "Shared immunoproteome for ovarian cancer diagnostics and immunotherapy: potential theranostic approach to cancer." J Proteome Res 6(7): 2509-17.
- Pinto-Plata, V., J. Toso, et al. (2007). "Profiling serum biomarkers in patients with COPD: associations with clinical parameters." Thorax 62(7): 595-601.
- Potter, J. D. (2005). "Epidemiology informing clinical practice: from bills of mortality to population laboratories." Nat Clin Pract Oncol 2(12): 625-34.
- Prorok, P. C., R. J. Connor, et al. (1990). "Statistical considerations in cancer screening programs." Urol Clin North Am 17(4): 699-708.
- Psyrris, A., P. Kountourakis, et al. (2007). "Analysis of p53 protein expression levels on ovarian cancer tissue microarray using automated quantitative analysis elucidates prognostic patient subsets." Ann Oncol.
- Rodenhiser, D. and M. Mann (2006). "Epigenetics and human disease: translating basic biology into clinical applications." Cmaj 174(3): 341-8.
- Ruddon, R. W. (1995). Oncogenes. Cancer Biology. New York, Oxford University Press: 277-317.
- Ruddon, R. W. (1995). Tumor Suppressor Genes. Cancer Biology. New York, Oxford University Press: 318-340.
- Schulte, P. A. (1993). A Conceptual and Historical Framework for Molecular Epidemiology. Molecular Epidemiology: Principles and Practices, Academic Press: 3-43.
- Smogorzewska, A. and T. de Lange (2004). "Regulation of telomerase by telomeric proteins." Annu Rev Biochem 73: 177-208.
- Srinivas, P. R., M. Verma, et al. (2002). "Proteomics for cancer biomarker discovery." Clin Chem 48(8): 1160-9.
- Steinmaus, C., M. N. Bates, et al. (2006). "Arsenic methylation and bladder cancer risk in case-control studies in Argentina and the United States." J Occup Environ Med 48(5): 478-88.
- Sun, S. Y., N. Hail, Jr., et al. (2004). "Apoptosis as a novel target for cancer chemoprevention." J Natl Cancer Inst 96(9): 662-72.
- Tabori, U., S. Nanda, et al. (2007). "Younger age of cancer initiation is associated with shorter telomere length in li-fraumeni syndrome." Cancer Res 67(4): 1415-8.

- Taguchi, F., B. Solomon, et al. (2007). "Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study." J Natl Cancer Inst 99(11): 838-46.
- Tsao, M. S., G. Liu, et al. (2007). "Serum proteomic classifier for predicting response to epidermal growth factor receptor inhibitor therapy: have we built a better mousetrap?" J Natl Cancer Inst 99(11): 826-7.
- van der Greef, J., T. Hankemeier, et al. (2006). "Metabolomics-based systems biology and personalized medicine: moving towards n = 1 clinical trials?" Pharmacogenomics 7(7): 1087-94.
- Vaught, J. B. (2006). "Biorepository and biospecimen science: a new focus for CEBP." Cancer Epidemiol Biomarkers Prev 15(9): 1572-3.
- Vidal, M. (2001). "A biological atlas of functional maps." Cell 104(3): 333-9.
- Wang, L., H. Liu, et al. (2006). "Association of genetic variants of O6-methylguanine-DNA methyltransferase with risk of lung cancer in non-Hispanic Whites." Cancer Epidemiol Biomarkers Prev 15(12): 2364-9.
- Yanagisawa, K., S. Tomida, et al. (2007). "A 25-signal proteomic signature and outcome for patients with resected non-small-cell lung cancer." J Natl Cancer Inst 99(11): 858-67.
- Yu, H. and T. Rohan (2000). "Role of the insulin-like growth factor family in cancer development and progression." J Natl Cancer Inst 92(18): 1472-89.



## Nikou, Roshan

---

**From:** Graduate.Council.Web.Site@www.uky.edu  
**Sent:** Wednesday, November 12, 2008 12:07 PM  
**To:** Nikou, Roshan  
**Cc:** Price, Cleo  
**Subject:** Investigator Report

AnyForm User: [www.uky.edu](http://www.uky.edu)  
AnyForm Document: <http://www.research.uky.edu/gc/GCInvestigatorReport.html>  
AnyForm Server: [www.uky.edu](http://www.uky.edu) (/www/htdocs/AnyFormTurbo/AnyForm.php)  
Client Address: 128.163.192.151

College/Department/Unit: = CPH 613  
Category: = New  
Date\_for\_Council\_Review: = Nov. 13, 2008  
Recommendation\_is: = Approve  
Investigator: = Chris Schardl  
E-mail\_Address = [schardl@uky.edu](mailto:schardl@uky.edu)

1\_\_Modifications: = A D-grade should not be indicated in the syllabus. Graduate courses only carry A, B, C, and E.  
Academic Integrity & Honesty: For penalties for cheating or plagiarism, see Student Code of Conduct, part II, section 6.4.3.A.3.  
2\_\_Considerations: =  
3\_\_Contacts: =  
4\_\_Additional\_Information: = Very well documented, includes full syllabus and calendar.

--  
AnyForm/PHP3 0.1

AnyFormRandomSeqNo: 12448172



UNIVERSITY OF KENTUCKY

*Dream · Challenge · Succeed*

**COLLEGE OF PUBLIC HEALTH**

**RECEIVED**

DEC 10 08

OFFICE OF THE  
SENATE COUNCIL

**MEMORANDUM**

**TO:** Health Care Colleges Council

**FROM:** Linda A. Alexander, EdD  
Associate Dean for Academic Affairs

**SUBJECT:** Proposal for CPH 613 Molecular Epidemiology

**DATE:** August 29, 2008

It is the intention of the Department of Epidemiology in the College of Public Health to formally establish a course to teach students in the MPH degree program about the principles underlying biomarker discovery and development. The course has been taught on other previous occasions as a special topics course and was very well received by students. It is being added to the concentration area's list of selectives.

This course proposal has been reviewed and approved by the Academic Affairs Committee and the Faculty Council, according to our college's established bylaws.

Further information about this course can be obtained by contacting the course director, Dr. Andre Baron via phone at 323-1729 or via email at [a.baron@uky.edu](mailto:a.baron@uky.edu).

TO: Linda Alexander  
Associate Dean for Academic Affairs

CC: Marta Menciondo  
Chair, Academic Affairs Committee

CC: Andre Baron

FROM: Glyn G. Caldwell  
Chair, Faculty Council

DATE: June 26, 2008

SUBJECT: Approval of CPH 613 Molecular Epidemiology

On June 26, 2008, the Faculty Council of the College of Public Health unanimously approved the course CPH 613 Molecular Epidemiology.

MEMORANDUM

To: Faculty Council

From: Marta S. Mendiondo *Marta S. Mendiondo*  
Chair, Academic Affairs Committee

Date: June 17, 2008

The Academic Affairs committee approved the proposed new course, CPH 613 Molecular Epidemiology.

**UNIVERSITY SENATE REVIEW AND CONSULTATION SUMMARY SHEET**

**Proposal Title:** CPH 613 MOLECULAR EPIDEMIOLOGY

**Proposal Contact:** Thomas Tucker  
 121 Washington Avenue Room 113  
 219-0773 ext 225 [tct@kcr.uky.edu](mailto:tct@kcr.uky.edu)

Becki Flanagan  
 CPH Office of Academic Affairs  
 121 Washington Avenue Room 110  
 218-2092 [becki@uky.edu](mailto:becki@uky.edu)

**Instruction:** To facilitate the processing of this proposal please identify the groups or individuals reviewing the proposal, identify a contact person for each entry, provide the consequences of the review (specifically, approval, rejection, no decision and vote outcome, if any) and please attach a copy of any report or memorandum developed with comments on this proposal.

<b>Reviewed By</b>	<b>Contact person</b>	<b>Consequences of Review</b>	<b>Date of Proposal Review</b>	<b>Review Summary Attached?</b>
Dept of Epidemiology	Thomas Tucker, Chair	Approved	4-30-08	Yes
Academic Affairs Committee	Marta Mendiondo, Chair	Approved	6-17-08	Yes
Faculty Council	Glyn Caldwell, Chair	Approved	7-17-08	Yes
Office of Academic Affairs	Linda Alexander, Associate Dean	Approved	8-28-09	Yes